CA58471K2020
© Globe Newswire
15.12.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
News Preview
THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) WITH THE FOOD AND DRUG ADMINISTRATION (FDA) IN H1 2026...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
05.12.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
News Preview
Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA / ACCESS Newswire / December 5, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.12.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President
News Preview
Carolyn Bonner succeeds James (“Jim”) Quinlan who has resigned for health reasons after taking medical leave in September 2025 Carolyn Bonner succeeds James (“Jim”) Quinlan who has resigned for health reasons after taking medical leave in September 2025...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© ACCESSWIRE
01.12.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President
News Preview
Carolyn Bonner Succeeds James ('Jim') Quinlan Who Has Resigned for Health Reasons After Taking Medical Leave in September 2025 PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / December 1, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
24.11.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers
News Preview
November is Men’s Health Awareness Month, a time to spotlight the latest medical breakthroughs that are transforming how we detect and treat cancer in men....
Themefolio
Profiler
Peergroup
© ACCESSWIRE
17.11.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
News Preview
SKNJCT-003 Doxorubicin containing Microneedle Array (D-MNA) clinical development program to non-invasively treat BCC aligns with national priorities of public health impact, unmet medical need, access, affordability, domestic manufacturing and rare-disease alignment. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / November 17, 2025 / Medicus Pharma...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.11.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights
News Preview
Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / November 14, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
13.11.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
News Preview
THE SKNJCT-003 CLINICAL STUDY EXPANSION INTO THE UNITED KINGDOM TO FURTHER ENABLE GLOBAL PATIENT RECRUITMENT AND CLINICAL DATASET TOWARD A PIVOTAL STUDY PROGRAM PHILADELPHIA, PA / ACCESS Newswire / November 13, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advan...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome
News Preview
Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000 people worldwide that can develop 500-1000 Basal Cell Carcinoma (BCC) lesions over lifetime Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000 pe...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
29.10.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome
News Preview
Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000 people worldwide that can develop 500-1000 Basal Cell Carcinoma (BCC) lesions over lifetime PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 29, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the &q...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
22.10.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
News Preview
CLEVELAND CLINIC ABU DHABI (CCAD) IS THE PRINCIPAL INVESTIGATOR IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PA / ACCESS Newswire / October 22, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disru...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.10.2025
MDCX
LISTED
TSX
Three Biotech Companies Redefining Value Creation Through Dual Strategies
News Preview
The Rise of Multi-Dimensional Biotech BRISTOL, TN, TN / ACCESS Newswire / October 14, 2025 / For decades, biotechnology investing was a binary game - a single trial failure could erase years of progress and billions in shareholder value. Yet a new generation of public life sciences companies is rewriting that equation by diversifying not just produ...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ACCESSWIRE
14.10.2025
MDCX
LISTED
TSX
The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets
News Preview
BRISTOL, TN, NY / ACCESS Newswire / October 14, 2025 / Most biotech stories collapse on a single product failure. Medicus Pharma Ltd (NASDAQ:MDCX) built three distinct shots at blockbuster markets.The NASDAQ-listed company is developing Skinject, a dissolvable microneedle array delivering doxorubicin for basal cell carcinoma [1]. It acquired Tevere...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
13.10.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025
News Preview
EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A FIRESIDE CHAT WITH EQUITY RESEARCH ANALYST PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 13, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel a...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.10.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE
News Preview
EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A PANEL DISCUSSIONThe Summit theme "unlocking the $1 Trillion Wealth transfer in Dubai" PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 7, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on ad...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
29.09.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject
News Preview
The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of the skin using dissolvable Doxorubicin-containing Microneedle arrays (D-MNA) representing ~$2 billion in potential market opportunityThe Company plans to complete patient recruitment for SKNJCT-003 before the end of Q4 2025...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
24.09.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. To Present at Brookline Capital Markets
News Preview
The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC) and development of Teverelix, a next generation GnRH Antagonist as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate CancerD-MNA and Teve...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
18.09.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing
News Preview
The Company plans to use the proceeds to accelerate the development of Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~ $6 billion in potential market opportunity PHILADELPHIA, PA / ACCESS Newswire / September 18, 2025 / Med...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.09.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
News Preview
CLEVELAND CLINIC ABU DHABI (CCAD) HAS COMMENCED RECRUITMENT IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / September 8, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentiall...
Themefolio
Profiler
Peergroup
© Newsfile
02.09.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Completes Acquisition of Antev Limited
News Preview
Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6 billion in potential market opportunityPatrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of D...
Themefolio
Profiler
Peergroup
© Newsfile
21.08.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights
News Preview
US Food and Drug Administration (FDA) has accepted the company's Type C meeting request and SKNJCT-003 Phase 2 study has randomized more than 75% of patientsPhiladelphia, Pennsylvania--(Newsfile Corp. - August 21, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinic...
Themefolio
Profiler
Peergroup
© Newsfile
23.07.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders
News Preview
The Company added Congresswoman Cathy McMorris Rodgers & Ajay Raju, Esq. to the Board of Directors.Philadelphia, Pennsylvania--(Newsfile Corp. - July 23, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the voting results of the Company's annual and special meeting (the "Meeting") of shareholders that w...
Themefolio
Profiler
Peergroup
© Newsfile
21.07.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025
News Preview
Executive Chairman & CEO of the Company to Participate in a Fireside ChatPhiladelphia, Pennsylvania--(Newsfile Corp. - July 21, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the scheduling of the Fireside chat of Dr. Raza Bokhari, Executive Chairman and CEO, at the BTIG Virtual Biotech Conference 202...
Themefolio
Profiler
Peergroup
© Newsfile
08.07.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)
News Preview
The Company's aim is to seek FDA consent to fast track the Clinical Development Program to treat Basal Cell Carcinoma (BCC) of the skin using Dissolvable Doxorubicin-containing Microneedle Arrays (D-MNA)Philadelphia, Pennsylvania--(Newsfile Corp. - July 8, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announc...
Themefolio
Profiler
Peergroup
© Newsfile
30.06.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK
News Preview
Antev Shareholders to Receive Aggregate ~17% Equity Stake in Medicus plus US$65 Million in Contingent PaymentsPhiladelphia, Pennsylvania--(Newsfile Corp. - June 30, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Antev Ltd. ("Antev"), a UK-based clinical-stage drug development company, announced today that they have entered into a defini...
Themefolio
Profiler
Peergroup
© Newsfile
23.06.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer
News Preview
Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Basal Cell Carcinoma (BCC) Using Novel Doxorubicin Containing Microneedle Arrays (D-MNA)Philadelphia, Pennsylvania--(Newsfile Corp. - June 23, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the appointment of Andrew Smith as Chi...
Themefolio
Profiler
Peergroup
© Newsfile
12.06.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. to Present at 2025 Bio International Convention
News Preview
Company Executive Chairman & CEO to Provide Corporate Updates on June 17th 2025Philadelphia, Pennsylvania--(Newsfile Corp. - June 12, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the schedule of the presentation of Dr. Raza Bokhari, Executive Chairman and CEO, at 2025 Bio International Convention.Ev...
Themefolio
Profiler
Peergroup
© Newsfile
09.06.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses
News Preview
Company Is Advancing Use of Novel Doxorubicin-containing Microneedle Array (D-MNA) Patch in Veterinary Oncology as an Orphan DrugPhiladelphia, Pennsylvania--(Newsfile Corp. - June 9, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce submission of a comprehensive product development plan to treat external...
Themefolio
Profiler
Peergroup
© Newsfile
02.06.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering
News Preview
Philadelphia, Pennsylvania--(Newsfile Corp. - June 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the closing of its previously announced public offering of 2,260,000 units, on a "best-efforts" basis, at a price of $3.10 per unit. Each unit consisted of one common share of the Company and one warrant to purchase one c...
Themefolio
Profiler
Peergroup
© Newsfile
30.05.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering
News Preview
Philadelphia, Pennsylvania--(Newsfile Corp. - May 29, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the pricing of its public offering of 2,260,000 units, on a "best-efforts" basis, at a price of $3.10 per unit. Each unit consists of one common share of the Company and one warrant to purchase one common share. The warra...
Themefolio
Profiler
Peergroup
© Newsfile
22.05.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
News Preview
The Clinical Study Is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAEPhiladelphia, Pennsylvania--(Newsfile Corp. - May 22, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce that it has received study may proceed approval from the UAE DOH to...
Themefolio
Profiler
Peergroup
© Newsfile
28.04.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction
News Preview
Antev Shareholders to Receive Aggregate ~19% Equity Stake in Medicus, Plus US$65 Million in Contingent PaymentsAntev is developing Teverelix, A next generation GnRH Antagonist, as first in class market product for Acute Urinary Retention (AUR) and high CV risk Prostate CancerPhiladelphia, Pennsylvania--(Newsfile Corp. - April 28, 2025) - Medicus Ph...
Themefolio
Profiler
Peergroup
© Newsfile
21.04.2025
MDCX
LISTED
TSX
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
News Preview
The Institutional Review Board Has Approved the Increase in Number of Patients from Sixty (60) to Ninety (90).The Company to Expand the Study into Additional Trial Sites in EuropePhiladelphia, Pennsylvania--(Newsfile Corp. - April 21, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce that Institutional...
Themefolio
Profiler
Peergroup
© Newsfile
10.03.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering
News Preview
Philadelphia, Pennsylvania--(Newsfile Corp. - March 10, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the closing of its previously announced Tier II Regulation A offering of 1,490,000 units, on a "best-efforts" basis, at a price of $2.80 per unit. Each unit consisted of one common share of the Company and one warrant t...
Themefolio
Profiler
Peergroup
© Newsfile
07.03.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering
News Preview
Philadelphia, Pennsylvania--(Newsfile Corp. - March 6, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the pricing of its Tier II Regulation A offering of 1,490,000 units, on a "best-efforts" basis, at a price of $2.80 per unit. Each unit consists of one common share of the Company and one warrant to purchase one common s...
Themefolio
Profiler
Peergroup
© Newsfile
06.03.2025
MDCX
LISTED
TSX
Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
News Preview
The Interim Analysis Showed Complete Clinical Clearance of More than Sixty (60%) PercentPhiladelphia, Pennsylvania--(Newsfile Corp. - March 6, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce a positively trending interim analysis for SKNJCT-003 Phase 2 clinical study to non-invasively treat basal cell...
Themefolio
Profiler
Peergroup
© Newsfile
28.10.2024
MDCX
LISTED
TSX
Medicus Pharma Ltd. Announces Share Consolidation in Anticipation of Proposed U.S. Listing
News Preview
Toronto, Ontario--(Newsfile Corp. - October 28, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") today announced that it has completed a consolidation of its common shares on a 2-to-1 basis (the "Consolidation").The Company has completed the Consolidation in connection with its proposed U.S. initial public offering and applicatio...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
